Search results
Your search for Supportan returned no results
Showing 391 to 405 of 660 results for supporting
Showing 391 to 405 of 660 results for supporting
NICE has developed a medtech innovation briefing (MIB) on Aquablation robotic therapy for lower urinary tract symptoms caused by benign prostatic hyperplasia .
Developmental follow-up of children and young people born preterm (NG72)
This guideline covers the developmental follow-up of babies, children and young people under 18 years who were born preterm (before 37+0 weeks of pregnancy). It explains the risk of different developmental problems and disorders, and specifies what extra assessments and support children born preterm might need during their growth and development.
Specialist neonatal respiratory care for babies born preterm (QS193)
This quality standard covers neonatal respiratory support in hospital for babies born preterm (before 37 weeks of pregnancy). It describes high-quality care in priority areas for improvement.
View quality statements for QS193Show all sections
Sections for QS193
- Quality statements
- Quality statement 1: Respiratory support soon after birth
- Quality statement 2: Minimally invasive administration of surfactant
- Quality statement 3: Invasive ventilation
- Quality statement 4: Oxygen saturation
- Quality statement 5: Involving parents and carers
- Update information
- About this quality standard
This quality standard covers road-traffic-related air pollution and its impact on health. It describes high-quality actions in priority areas for improvement.
View quality statements for QS181Show all sections
Sections for QS181
- Quality statements
- Quality statement 1: Strategic plans
- Quality statement 2: Planning applications
- Quality statement 3: Reducing emissions from public sector vehicle fleets
- Quality statement 4: Advice for people with chronic respiratory or cardiovascular conditions
- Update information
- About this quality standard
This quality standard covers renal replacement therapy services for adults with kidney failure. It includes treatment options, such as dialysis and kidney transplant. It describes high-quality care in priority areas for improvement.
View quality statements for QS72Show all sections
Sections for QS72
- Quality statements
- Quality statement 1: Education programmes
- Quality statement 2: Transplantation – pre-emptive
- Quality statement 3: Transplantation – on dialysis
- Quality statement 4: Dialysis access preparation
- Quality statement 5: Home-based dialysis
- Quality statement 6: Patient transport
- Quality statement 7: Transplantation – rapid access to a specialist histopathology service
the recommendations may result in specific changes in practice around supporting women's choice of place of birth and routine...
Early value assessment (EVA) guidance on digital front door technologies to gather service user information for NHS Talking Therapies for anxiety and depression assessments.
NICE has developed a medtech innovation briefing (MIB) on microINR for anticoagulation therapy .
Outside interests of the NICE board
Past technology appraisal appeals and decisions
This guideline covers how to improve services for people aged 14 and above who have been diagnosed as having coexisting severe mental illness and substance misuse. The aim is to provide a range of coordinated services that address people’s wider health and social care needs, as well as other issues such as employment and housing.
Brentuximab vedotin for treating CD30-positive cutaneous T-cell lymphoma (TA577)
Evidence-based recommendations on brentuximab vedotin (Adcetris) for treating CD30-positive cutaneous T-cell lymphoma in adults.
YOURmeds for medication support in long-term conditions (MIB289)
NICE has developed a medtech innovation briefing (MIB) on YOURmeds for medication support in long-term conditions .
Evidence-based recommendations on dabigatran etexilate (Pradaxa) for preventing stroke and systemic embolism in adults with non-valvular atrial fibrillation.
Evidence-based recommendations on lenalidomide (Revlimid) for treating myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality in adults.
View recommendations for TA322Show all sections